FibroGen, Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 38,636 shares of the business’s stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $56.13, for a total value of $2,168,638.68. Following the completion of the sale, the chief executive officer now owns 3,144,573 shares in the company, valued at approximately $176,504,882.49. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.01). The business had revenue of $29.00 million for the quarter, compared to analysts’ expectations of $34.80 million. FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%.

WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/01/insider-selling-fibrogen-inc-fgen-ceo-sells-38636-shares-of-stock.html.

Several equities research analysts have commented on FGEN shares. Jefferies Group LLC started coverage on FibroGen in a research note on Monday, July 10th. They issued a “buy” rating and a $50.00 target price on the stock. Goldman Sachs Group, Inc. (The) lowered FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price target on the stock. in a research report on Friday, July 21st. BidaskClub lowered FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Stifel Nicolaus boosted their price target on FibroGen from $38.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Finally, Citigroup Inc. boosted their price target on FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a research report on Tuesday, August 8th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. FibroGen presently has a consensus rating of “Buy” and a consensus price target of $65.67.

Institutional investors and hedge funds have recently modified their holdings of the stock. New York State Common Retirement Fund increased its position in shares of FibroGen by 24.0% during the second quarter. New York State Common Retirement Fund now owns 67,700 shares of the biopharmaceutical company’s stock valued at $2,187,000 after acquiring an additional 13,099 shares during the last quarter. Prudential Financial Inc. increased its position in shares of FibroGen by 9.6% during the second quarter. Prudential Financial Inc. now owns 448,780 shares of the biopharmaceutical company’s stock valued at $14,496,000 after acquiring an additional 39,430 shares during the last quarter. FMR LLC increased its position in shares of FibroGen by 96.9% during the second quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock valued at $107,753,000 after acquiring an additional 1,641,423 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of FibroGen by 0.4% during the first quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock valued at $3,354,000 after acquiring an additional 504 shares during the last quarter. Finally, Citigroup Inc. increased its position in shares of FibroGen by 37.3% during the second quarter. Citigroup Inc. now owns 40,046 shares of the biopharmaceutical company’s stock valued at $1,294,000 after acquiring an additional 10,876 shares during the last quarter. 47.49% of the stock is owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.